Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.66 |
| ▸ | FABP1 | P07148 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5376378 | 0.81 | SMN1; SMN2 (0.64) | MEN1KMT2AALDH1A1TP53LMNA | |
| SCHEMBL5426560 | 0.81 | MEN1 (0.74) | MEN1KMT2AALDH1A1TSHRTP53 | |
| SCHEMBL5371903 | 0.80 | MEN1 (0.77) | MEN1KMT2APKM | |
| SCHEMBL5373527 | 0.79 | SMN1; SMN2 (0.61) | MEN1KMT2AALDH1A1TP53LMNA | |
| SCHEMBL5373430 | 0.78 | KMT2A (0.70) | MEN1KMT2AALDH1A1TSHRTP53 | |
| SCHEMBL5376813 | 0.78 | LMNA (0.60) | MEN1KMT2ATP53LMNAPKM | |
| SCHEMBL5376988 | 0.78 | LMNA (0.60) | MEN1KMT2ATP53LMNAPKM | |
| SCHEMBL6676305 | 0.74 | POLB (0.75) | MEN1KMT2AALDH1A1TP53LMNA | |
| SCHEMBL5372024 | 0.74 | KMT2A (0.71) | MEN1KMT2ATP53MAPTLMNA | |
| SCHEMBL5368637 | 0.74 | TP53 (0.83) | MEN1KMT2AALDH1A1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | MEN1 4855/4885KMT2A 3530/4885FABP1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.